Emery Pharma Co-Sponsors PDA West Coast Event on CMC Strategy for Parenteral and Novel Drug Modalities

Emery Pharma announced its role as co-sponsor and host of the Parenteral Drug Association (PDA) – West Coast Chapter upcoming industry program focused on CMC considerations for parenteral drug products and novel therapeutic modalities. The event will take place Thursday, October 30, 2025, from 5:00 PM to 8:30 PM PT at Emery Pharma’s headquarters in Alameda, California.

The panel will bring together leaders across drug development, testing, and manufacturing to discuss regulatory expectations, innovation strategies, and scientific best practices to ensure efficient transition from laboratory research to clinical success.

Featured speakers include:
• Moderator: Aryo Nikopour — VP Global Pharma, Nelson Labs
• Milan Tomic, Ph.D. — CEO, Albrem BioPharma
• Ron Najafi, Ph.D. — President & CEO, Emery Pharma
• Laurent Classie, MBA — CEO, Clean Cells
• Fariba Chalajour, MD — Site Director, Comparative Biosciences (a division of GD3)

“We are thrilled to partner with PDA West Coast to gather experts advancing next-generation sterile pharmaceuticals,” said Dr. Ron Najafi, President & CEO of Emery Pharma. “As injectable modalities evolve, early CMC alignment is mission-critical. By sharing real-world experience and emerging innovation, we aim to accelerate safe and effective medicines to patients worldwide.”

The evening will feature presentations, a moderated discussion, interactive Q&A, and dedicated networking time with regulatory, analytical, and CMC professionals across the West Coast pharma ecosystem.

Register here: https://luma.com/mk0bunrv

About Emery Pharma

Emery Pharma is a leading analytical and bioanalytical contract research organization based in Alameda, California, recognized for its scientific leadership in impurity analysis and regulatory compliance. Specializing in GLP- and cGMP-compliant analytical testing, the company provides a comprehensive suite of services that support every stage of drug development—from early discovery through clinical trials and commercialization.

A pioneer in the development and validation of sensitive and specific assays for nitrosamine detection, Emery Pharma has played a key role in helping pharmaceutical sponsors and manufacturers navigate evolving FDA and ICH guidelines. The company’s cutting-edge capabilities in liquid chromatography-mass spectrometry (LC-MS/MS) and high-resolution mass spectrometry (HRMS) enable the precise quantification of trace-level nitrosamine impurities, including NDSRIs, NDMA and MNP, in complex matrices.

Emery Pharma also offers antibiotic screening, robust stability testing programs for both research-stage and commercial products, along with advanced analytical platforms such as nuclear magnetic resonance (NMR) and gas chromatography-mass spectrometry (GC-MS). Its team of interdisciplinary scientists delivers problem-solving, method development and investigational services with a strong focus on regulatory readiness and data integrity.

Driven by a commitment to scientific excellence and public health, Emery Pharma continues to advance the field of impurity profiling—ensuring safer medicines and contributing to industry-wide efforts to mitigate the risks associated with nitrosamines and other genotoxic contaminants.

For more information, visit us at emerypharma.com and follow us on LinkedIn.

Media Contact: Chris Purcell —Business Development Manager
Email: info@emerypharma.com
Phone: (510) 899-8800